Latest News on NTLA

Financial News Based On Company


Advertisement
Advertisement

Form 8K Intellia Therapeutics Inc For: 13 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-intellia-therapeutics-inc-for-13-november-93CH-4957941
This article reports on Intellia Therapeutics Inc.'s Form 8K filing for November 13. The company's stock symbol NTLA is mentioned with an 8.06% change. The content primarily serves as a placeholder or brief announcement from Investing.com.

Intellia Therapeutics Stock In Focus As HAE Gene Editing Wins Priority Review

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellia-therapeutics-stock-in-focus-as-hae-gene-editing-win
Intellia Therapeutics is gaining attention as its HAE gene editing therapy, lonvo z, receives priority FDA review, and its nex z therapy for transthyretin amyloidosis completes Phase 3 enrollment. These advancements signal a shift for the company from an R&D focus to potential commercial execution in rare disease markets. Despite ongoing net losses, the company's investment narrative is bolstered by these regulatory and clinical milestones, with analysts projecting significant future revenue and earnings growth.

Form 8K Intellia Therapeutics Inc For: 13 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-8k-intellia-therapeutics-inc-for-13-november-93CH-4982049
This article announces that Intellia Therapeutics Inc. filed a Form 8K on November 13. The brief notice highlights the filing of the regulatory document, a common disclosure for significant company events. The article provides no further details on the content of the 8K filing itself, serving primarily as an alert to the filing.

Intellia Therapeutics' One-Time HAE Therapy Cuts Attacks 87% in Trial as FDA Decision Nears

https://finance.yahoo.com/healthcare/articles/intellia-therapeutics-one-time-hae-211457517.html
Intellia Therapeutics has presented promising clinical data and outlined launch plans for lonvo-z, its investigational one-time gene-editing treatment for hereditary angioedema (HAE). The therapy demonstrated an 87% mean reduction in HAE attacks in a Phase 3 trial, with 62% of participants becoming attack-free. The FDA has granted priority review for lonvo-z, with a decision expected by March 10, 2027, and no advisory committee meeting currently planned.

Intellia Says CRISPR Therapy Lonvo-z Cut Hereditary Angioedema Attacks 89% for Up to Four Years

https://www.techtimes.com/articles/330661/20261113/intellia-says-crispr-therapy-lonvo-z-cut-hereditary-angioedema-attacks-89-four-years.htm
Intellia Therapeutics announced that its CRISPR gene-editing therapy, lonvoguran ziclumeran (lonvo-z), reduced hereditary angioedema (HAE) attack rates by 89% for up to four years, with patients on the 50 mg dose becoming free of long-term preventive drugs. The FDA has set a March 10, 2027, target date for a decision on lonvo-z, which could become the first in vivo CRISPR medicine. While the therapy shows promising durability and effectiveness in reducing kallikrein levels, questions remain regarding long-term safety, cost, and the implications of a permanent gene edit.
Advertisement

Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026

https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-presents-additional-positive-clinical-and
Intellia Therapeutics announced additional positive clinical and patient-reported data for its CRISPR gene editing candidate, lonvoguran ziclumeran (lonvo-z), for hereditary angioedema (HAE) at the ACAAI 2026 Annual Scientific Meeting. The data highlighted an 81% reduction in monthly attack rate among patients previously on long-term prophylaxis, with 100% of 50 mg lonvo-z patients becoming LTP-free. Patient interviews indicated high satisfaction and perception of lonvo-z as an optimal, one-time HAE therapy.

Intellia Therapeutics (NTLA) Completes Phase 3 Enrollment As Investors Ask If It Is Still A Bargain

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellia-therapeutics-ntla-completes-phase-3-enrollment-as-i
Intellia Therapeutics (NTLA) has completed enrollment in its MAGNITUDE-2 Phase 3 trial for nex-z, a significant milestone for the gene-editing company. Despite recent short-term stock pressure, the company is viewed as 52% undervalued by analysts, with a fair value of $23.11 compared to its current price of $11.17. Investors are now evaluating if the recent positive momentum signals a beginning of a re-rating or if the easy upside has already been captured.

Intellia Therapeutics to Present at Jefferies Global Healthcare Conference in London

https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-present-jefferies-global-healthcare
Intellia Therapeutics, Inc. (Nasdaq: NTLA) announced it will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, at 8:30 a.m. GMT / 3:30 a.m. ET. A live webcast of the presentation will be available on the company's website, with a replay accessible for approximately 90 days. Intellia Therapeutics is a clinical-stage biopharmaceutical company focused on CRISPR gene editing to develop potentially curative treatments for severe diseases.

A passive State Street stake exceeds 5% of Intellia Therapeutics (NTLA).

https://www.stocktitan.net/sec-filings/NTLA/schedule-13g-intellia-therapeutics-inc-passive-investment-disclosure--0df09f75d88e.html
State Street Corporation has reported a passive investment in Intellia Therapeutics (NTLA), acquiring beneficial ownership of 7,809,060 shares, which represents 5.6% of the company's common stock as of September 30, 2026. The filing indicates shared voting power over 7,473,384 shares and shared dispositive power over 7,809,060 shares, with no sole voting or dispositive control. Several State Street Global Advisors subsidiaries were identified as having acquired the security.

Intellia Therapeutics to Present at Jefferies Global Healthcare Conference in London

https://www.globenewswire.com/news-release/2026/11/10/3399407/0/en/intellia-therapeutics-to-present-at-jefferies-global-healthcare-conference-in-london.html
Intellia Therapeutics, Inc. (Nasdaq: NTLA) announced it will present at the Jefferies Global Healthcare Conference in London on November 17, 2026, at 8:30 a.m. GMT. The presentation will be available via a live webcast on the company's website, with a replay available for approximately 90 days. Intellia Therapeutics is a clinical-stage biopharmaceutical company focused on CRISPR gene editing to develop treatments for severe diseases.
Advertisement

Intellia Therapeutics (NTLA) Stock Could Look Stretched On Phase 3 Trial Progress

https://sg.finance.yahoo.com/news/intellia-therapeutics-ntla-stock-could-052030558.html
Intellia Therapeutics (NTLA) has seen a significant stock price decline over the past five years, despite recent positive performance and fresh milestones in gene editing and late-stage programs. The article questions whether the current US$11.35 share price and market valuation are justified by its present sales and pipeline potential, especially considering its high Price/Sales (P/S) ratio compared to industry averages. It also highlights differing community views on whether the gene editing platform is undervalued or if the single-treatment model caps its upside.

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

https://www.globenewswire.com/news-release/2026/11/06/3397890/0/en/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Intellia Therapeutics, Inc. announced that on November 1, 2026, it awarded inducement grants to three new employees as a material inducement to employment. These grants consisted of time-based restricted stock units (RSUs) for an aggregate of 12,900 shares of Intellia’s common stock, vesting annually over three years. The awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to its 2024 Inducement Plan and approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).

Three new hires got Intellia stock awards that vest over three years if they keep working there.

https://www.stocktitan.net/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-v9abcwvxdbk1.html
Intellia Therapeutics (NTLA) announced inducement grants of restricted stock units (RSUs) totaling 12,900 common shares to three new employees on November 1, 2026. These RSUs will vest annually over three years, contingent upon the employees' continued service to the company. The awards were approved by Intellia's compensation committee under Nasdaq Listing Rule 5635(c)(4) and granted outside stockholder-approved equity incentive plans.

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-reports-inducement-grants-under-nasdaq-25
Intellia Therapeutics, Inc. announced that on November 1, 2026, it awarded inducement grants to three new employees as a material inducement to employment. These grants consisted of time-based restricted stock units (RSUs) for a total of 12,900 shares of common stock, vesting annually over three years. The awards were granted outside of stockholder-approved equity incentive plans, under Intellia’s 2024 Inducement Plan, and approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).

Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates

https://investingnews.com/intellia-therapeutics-announces-third-quarter-2026-financial-results-and-business-updates/
Intellia Therapeutics reported its third-quarter 2026 financial results and provided business updates, highlighting significant progress in its late-stage pipeline. The company is on track for the potential approval and commercial launch of lonvo-z, its one-time CRISPR-based therapy for Hereditary Angioedema (HAE), in early 2027. Intellia also completed enrollment for a Phase 3 trial of nex-z for ATTRv-PN and secured a $400 million term loan facility, extending its cash runway into 2028.
Advertisement

Form 8K Intellia Therapeutics Inc For: 5 November By Investing.com

https://in.investing.com/news/stock-market-news/form-8k-intellia-therapeutics-inc-for-5-november-93CH-5683533
This article reports on Intellia Therapeutics Inc.'s filing of a Form 8K on November 5. The company's stock symbol is NTLA, and it experienced a -5.36% change. The content highlights the routine reporting of corporate events.

Intellia Therapeutics Inc earnings missed by $0.11, revenue fell short of estimates

https://www.investing.com/news/earnings/intellia-therapeutics-inc-earnings-missed-by-011-revenue-fell-short-of-estimates-5004196
Intellia Therapeutics Inc (NASDAQ: NTLA) reported third-quarter EPS of $-0.91, missing analyst estimates by $0.11, and revenue of $7.16M, falling short of the consensus estimate of $10.23M. Despite the earnings miss, the company's stock price has shown a 3.10% increase over the last three months, though it is down 0.08% over the past year. InvestingPro rates Intellia Therapeutics Inc's financial health as "fair performance."

INTELLIA THERAPEUTICS ($NTLA) Releases Q3 2026 Earnings

https://www.quiverquant.com/news/INTELLIA+THERAPEUTICS+%28%24NTLA%29+Releases+Q3+2026+Earnings
Intellia Therapeutics ($NTLA) reported its Q3 2026 earnings, missing both earnings per share and revenue estimates. The company reported an EPS of -$0.91 against an -$0.81 estimate and revenue of $7.16 million against a $10.67 million estimate. Insider trading activity for NTLA over the past six months shows seven sales and no purchases by executives, while institutional investors showed mixed activity, with 182 adding shares and 119 decreasing positions.

Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates

https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-third-quarter-2026-financial
Intellia Therapeutics reported its third-quarter 2026 financial results and provided business updates, highlighting its progress toward commercializing lonvo-z for Hereditary Angioedema (HAE) with a PDUFA date of March 10, 2027. The company also announced the completion of enrollment for its MAGNITUDE-2 Phase 3 trial and detailed its financial position, expecting existing cash resources to fund operations into 2028. Additionally, Intellia appointed a new Chief Medical Officer and secured a non-dilutive term loan facility.

Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)

https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-completes-enrollment-phase-3-magnitude-2
Intellia Therapeutics has completed enrollment for its Phase 3 MAGNITUDE-2 clinical trial of nexiguran ziclumeran (nex-z) for patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). Nex-z is an investigational CRISPR-based therapeutic designed to inactivate the TTR gene, aiming to provide a potentially lifelong reduction in TTR protein after a single treatment. The trial, involving approximately 60 patients, will evaluate the efficacy and safety of nex-z, representing a significant step towards a new treatment for this debilitating disease.
Advertisement

Intellia Therapeutics (NTLA) Could Be 49% Undervalued After New Phase 1 Data Plans

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellia-therapeutics-ntla-could-be-49-undervalued-after-new
Intellia Therapeutics (NTLA) is drawing investor attention as it plans to release new Phase 1 data for its CRISPR-based candidate, nexiguran ziclumeran, this month. Despite recent share price fluctuations, the stock is considered by some analyses to be 49% undervalued, with a fair value of $23.11 compared to its current price of $11.86. However, another view suggests the stock is rich on sales, trading significantly above industry and peer P/S ratios, highlighting potential valuation risks if CRISPR pricing or uptake expectations are not met.

Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran Medical Congress Presentations

https://investingnews.com/intellia-therapeutics-announces-upcoming-nexiguran-ziclumeran-medical-congress-presentations/
Intellia Therapeutics will present new clinical data for nexiguran ziclumeran (nex-z) at two medical meetings in November. The presentations will include cardiac outcomes from a Phase 1 trial in ATTRv-PN patients with mixed phenotype at the American Heart Association Scientific Sessions and long-term follow-up data from the Phase 1 trial in ATTRv-PN patients at the International Society of Amyloidosis 2026 Symposium. Nex-z is a CRISPR/Cas9 gene-editing therapy being investigated as a potential one-time treatment for ATTR amyloidosis.

Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations

https://www.globenewswire.com/news-release/2026/11/03/3394179/0/en/intellia-therapeutics-announces-upcoming-nexiguran-ziclumeran-nex-z-medical-congress-presentations.html
Intellia Therapeutics announced it will present new clinical data for its CRISPR-based gene editing therapy, nexiguran ziclumeran (nex-z), at two medical congresses in November. Presentations will include cardiac outcomes from the Phase 1 trial in ATTRv-PN patients with mixed phenotype at the American Heart Association Scientific Sessions, and up to four years of follow-up data in ATTRv-PN patients at the International Society of Amyloidosis Symposium. Nex-z, developed in collaboration with Regeneron Pharmaceuticals, aims to be a one-time treatment for transthyretin (ATTR) amyloidosis.

Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations

https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-upcoming-nexiguran-ziclumeran
Intellia Therapeutics announced it will present new clinical data on its gene-editing therapy, nexiguran ziclumeran (nex-z), at two medical meetings in November. Presentations at the American Heart Association Scientific Sessions 2026 and the International Society of Amyloidosis 2026 Symposium will highlight cardiac outcomes and long-term follow-up data from the Phase 1 clinical trial of nex-z in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). Nex-z, based on CRISPR/Cas9 technology, is being investigated as a potential one-time treatment for ATTR amyloidosis and has received Orphan Drug and RMAT designations.

Intellia Therapeutics, Inc. (NTLA) Seasonal returns chart

https://sg.finance.yahoo.com/quote/NTLA/seasonality/
This article from Yahoo Finance provides a seasonal returns chart for Intellia Therapeutics, Inc. (NTLA), displaying average monthly price returns from 2016 to 2026. It also includes current stock performance and general market data.
Advertisement

Upcoming Drug Data Could Reshape The Case For Intellia Therapeutics Stock

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/upcoming-drug-data-could-reshape-the-case-for-intellia-thera
Intellia Therapeutics recently presented positive data on lonvoguran ziclumeran for hereditary angioedema and received priority FDA review with a March 10, 2027 PDUFA date. This shift indicates the company is moving towards commercial execution for its lead CRISPR-based therapy. Upcoming data and commercial buildout will be crucial for shareholders, though risks like competition and potential shareholder dilution remain.

Intellia Therapeutics shares may move 3.8% on earnings release

https://www.investing.com/news/stock-market-news/intellia-therapeutics-shares-may-move-38-on-earnings-release-93CH-4988131
Intellia Therapeutics Inc. (NTLA) shares are projected to move 3.8% when the company reports earnings on November 6, according to options data. Historically, the actual stock price movement has often exceeded the implied move from options data in five out of the past eight earnings announcements. The company has not yet confirmed the exact time of the earnings release.

Intellia Therapeutics, Inc. Initial Statement of Beneficial Ownership

https://www.stocktitan.net/sec-filings/NTLA/form-3-intellia-therapeutics-inc-initial-statement-of-beneficial-owne-97080f9415cd.html
This article details an initial statement of beneficial ownership (Form 3) filed by Jing L. Marantz, the EVP and Chief Medical Officer of Intellia Therapeutics, Inc. (NTLA), with the SEC. The filing, dated October 28, 2026, indicates that no securities are beneficially owned by Marantz at the time of this initial statement. It provides information regarding the company's SEC filings, stock data, and recent news.

Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026

https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-upcoming-lonvoguran-ziclumeran
Intellia Therapeutics announced its participation in the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting with two oral and five poster presentations on lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE). The presentations will include four-year follow-up data and patient perspectives on life after lonvo-z treatment. Intellia will also host an investor webcast on November 12, 2026, to discuss presentation highlights, HAE key opinion leader perspectives, and preparations for lonvo-z's commercial launch, following the FDA's acceptance of its Biologics License Application with Priority Review.

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

https://www.globenewswire.com/news-release/2026/10/28/3390758/0/en/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Intellia Therapeutics, Inc. (Nasdaq: NTLA) announced inducement grants awarded to its Executive Vice President and Chief Medical Officer, Jing Marantz, M.D., Ph.D., as a material inducement to employment. The grants, awarded on October 26, 2026, included non-qualified stock options for 275,061 shares and time-based restricted stock units for 199,822 shares. These awards were made outside of the company's stockholder-approved equity incentive plans, pursuant to Nasdaq Listing Rule 5635(c)(4).
Advertisement

Intellia Therapeutics' CMO Jing L. Marantz Files Initial Ownership Disclosure with No Securities Held

https://kalkinemedia.com/us/news/announcements/intellia-therapeutics-cmo-jing-l-marantz-files-initial-ownership-disclosure-with-no-securities-held
Jing L. Marantz, Executive Vice President and Chief Medical Officer of Intellia Therapeutics, Inc. (NASDAQ: NTLA), filed an initial beneficial ownership statement on October 28, 2026. The filing, which corresponds to a triggering event on October 26, 2026, explicitly states that Marantz holds no beneficial ownership of the company's securities. This disclosure confirms her lack of stock holdings upon her appointment as an officer.

Options on 275,061 shares go to Intellia Therapeutics (NTLA) medical chief with an $11.26 exercise price.

https://www.stocktitan.net/sec-filings/NTLA/form-4-intellia-therapeutics-inc-insider-trading-activity-bd2c839b02d2.html
Intellia Therapeutics' EVP, Chief Medical Officer, Jing L. Marantz, received 199,822 restricted stock units and options for 275,061 common shares on October 26, 2026. The options have an exercise price of $11.26 and vest over time, with 33% vesting on October 26, 2027, and the remaining 67% in 24 monthly installments. This grant is part of an insider trading activity report by the company.

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-reports-inducement-grants-under-nasdaq-24
Intellia Therapeutics announced inducement grants awarded to its Executive Vice President and Chief Medical Officer, Jing Marantz, M.D., Ph.D., as a material inducement to employment. The grants, consisting of stock options and restricted stock units, were issued on October 26, 2026, outside of stockholder-approved equity incentive plans but under the company's 2024 Inducement Plan. These awards were approved by independent directors in accordance with Nasdaq Listing Rule 5635(c)(4).

Intellia Therapeutics, Inc. Estimates – NASDAQ:NTLA

https://www.tradingview.com/symbols/NASDAQ-NTLA/financials-estimates/
This article provides an overview of financial actuals and analyst estimates for Intellia Therapeutics, Inc. (NASDAQ: NTLA) on TradingView. It allows users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform also enables comparison of actual results with average, high, and low estimates, and visualization of trends over time.

Intellia Therapeutics, Inc. Estimates – GETTEX:38I

https://www.tradingview.com/symbols/GETTEX-38I/financials-estimates/
This article provides access to financial actuals and analyst estimates for Intellia Therapeutics, Inc. (GETTEX:38I) through TradingView. Users can explore reported financial data, compare actual results with estimates, and visualize trends across income statements, balance sheets, cash flow statements, and valuation metrics. The platform emphasizes that this information is not investment advice and encourages users to conduct their own research.
Advertisement

Learn Why The Bull Case For Intellia Therapeutics Stock Could Change Following New CMO Appointment

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/learn-why-the-bull-case-for-intellia-therapeutics-stock-coul/amp
Intellia Therapeutics has appointed Dr. Jing L. Marantz as EVP and Chief Medical Officer, a move expected to enhance clinical and regulatory execution, especially for its late-stage programs in ATTR amyloidosis and hereditary angioedema. While her experience is a positive, the company still faces significant risks, including concentrated exposure to a few lead assets, ongoing losses, and cash burn, necessitating careful execution under the new leadership before further capital may be needed. Analysts project substantial revenue growth and a shift to profitability by 2029, dependent on successful clinical milestones and operational discipline.

Is Intellia Therapeutics (NTLA) Cheap Or Pricey On Its New Chief Medical Officer Appointment?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/is-intellia-therapeutics-ntla-cheap-or-pricey-on-its-new-chi
Intellia Therapeutics (NTLA) recently appointed Jing L. Marantz as EVP and Chief Medical Officer, impacting investor attention. The stock is currently trading at US$11.42, showing short-term gains but significant long-term losses. While one analysis suggests it is 52% undervalued with a fair value of $23.94, another view highlights its high price-to-sales ratio of 26.9x, suggesting it looks expensive on revenue.

Intellia Therapeutics, Inc. (NTLA) options chain

https://au.finance.yahoo.com/quote/NTLA/options/?date=1807833600&straddle=false&type=all
This article provides detailed options chain data for Intellia Therapeutics, Inc. (NTLA) as of October 16, 2026. It lists various call and put options expiring on April 16, 2027, including strike prices, last trade dates, last prices, bids, asks, changes, volumes, open interest, and implied volatility. The stock's price at close was $11.42, with an after-hours price of $11.26.

Intellia Therapeutics names Jing Marantz as chief medical officer

https://www.investing.com/news/company-news/intellia-therapeutics-names-jing-marantz-as-chief-medical-officer-93CH-4946370
Intellia Therapeutics, Inc. has announced the appointment of Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026. Dr. Marantz brings over 25 years of biopharmaceutical industry experience, including leading the development organization at Scholar Rock through the U.S. approval of ISEMBYLD. She will oversee translational, development, regulatory, and medical affairs functions at Intellia, a gene-editing company currently conducting Phase 3 clinical trials.

Intellia Therapeutics names Jing L. Marantz as new Chief Medical Officer to lead clinical and regulatory efforts.

https://pluang.com/en/news-feed/intellia-therapeutics-tunjuk-jing-l-marantz-sebagai-cmo
Intellia Therapeutics has appointed Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026. Dr. Marantz brings over 25 years of experience in drug development, particularly in rare diseases, and will oversee critical clinical and regulatory functions. Her leadership is aimed at accelerating the commercialization of Intellia's first in vivo gene editing product and advancing Phase 3 trials for transthyretin amyloidosis.
Advertisement

Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer

https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-appoints-jing-l-marantz-md-phd-chief
Intellia Therapeutics announced the appointment of Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026. Dr. Marantz brings over 25 years of biopharmaceutical industry experience, including successful rare disease therapy advancements. She will lead the company's translational, development, regulatory, and medical affairs functions, aiming to advance Intellia's gene-editing pipeline and commercialize its first in vivo gene editing product.

Intellia Therapeutics names new chief medical officer

https://www.streetinsider.com/Management+Changes/Intellia+Therapeutics+names+new+chief+medical+officer/27177082.html
Intellia Therapeutics (Nasdaq: NTLA) has appointed Dr. Jing L. Marantz as its new Executive Vice President and Chief Medical Officer, effective October 26, 2026. Dr. Marantz brings over 25 years of biopharmaceutical industry experience, including previous roles at Scholar Rock where she led the development and U.S. approval of ISEMBYLD. Her appointment comes as Intellia prepares to commercialize its first potential in vivo gene editing product and advance Phase 3 clinical trials.

Price to earnings forward of Intellia Therapeutics, Inc. – BX:38I

https://www.tradingview.com/symbols/BX-38I/financials-statistics-and-ratios/price-earnings-fwd/
This article provides financial information for Intellia Therapeutics, Inc. (BX:38I) on the TradingView platform, specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed with no trades at the time of publication. The page also lists various data providers and copyright information.

FDA Priority Review Could Be A Game Changer For Intellia Therapeutics Stock (NTLA)

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/fda-priority-review-could-be-a-game-changer-for-intellia-the
Intellia Therapeutics received FDA Priority Review for its hereditary angioedema drug, lonvoguran ziclumeran, and secured a $400 million debt facility. This accelerates regulatory review and provides funding flexibility, shifting the company's investment narrative from R&D to potential commercialization. While this offers significant upside, the company still faces operational risks due to its concentration on key drugs and continued unprofitability.

Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?

https://finance.yahoo.com/markets/stocks/articles/intellia-therapeutics-ntla-soars-7-105100001.html
Intellia Therapeutics (NTLA) shares rose 7.6% after the FDA accepted its biologics license application for lonvoguran ziclumeran with Priority Review, and the company secured a $400 million debt facility. Despite this, the stock carries a Zacks Rank #3 (Hold) due to unchanged earnings estimates, suggesting potential investors should monitor future revisions.
Advertisement

Intellia Therapeutics (NTLA) Pullback Puts Its CRISPR Valuation Story Back In Focus

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellia-therapeutics-ntla-pullback-puts-its-crispr-valuatio
Intellia Therapeutics (NTLA) has seen a recent share price pullback, prompting investors to re-evaluate its CRISPR-based drug pipeline and funding risks. Despite a 27.14% year-to-date gain, the stock experienced a 52.15% decline over the past year and an 8.08% drop in the last month. Analysts consider NTLA 51% undervalued with a fair value of $23.94, citing improving financial discipline and a robust cash runway, though potential setbacks in trials or heavy dilution remain risks.

Barclays Maintains Intellia Therapeutics(NTLA.US) With Sell Rating, Maintains Target Price $8

https://www.moomoo.com/news/post/1000681398/barclays-maintains-intellia-therapeutics-ntlaus-with-sell-rating-maintains-target
Barclays has reiterated its Sell rating on Intellia Therapeutics (NTLA.US) and maintained its target price at $8. This indicates that Barclays' analysts continue to have a bearish outlook on the company's stock performance.

Barclays Initiates Intellia Therapeutics at Underweight With $8 Price Target

https://www.moomoo.com/news/post/1000643368/barclays-initiates-intellia-therapeutics-at-underweight-with-8-price-target
Barclays has initiated coverage on Intellia Therapeutics (NASDAQ:NTLA) with an Underweight rating and a price target of $8. This indicates a bearish outlook on the company's stock by the financial institution.

To cover taxes, an Intellia Therapeutics (NTLA) officer sells 1,864 shares in a mandatory sale.

https://www.stocktitan.net/sec-filings/NTLA/form-4-intellia-therapeutics-inc-insider-trading-activity-1fdf2d773b78.html
Michael P. Dube, VP and Chief Accounting Officer of Intellia Therapeutics (NTLA), sold 1,864 common shares on October 2, 2026, at $12.43 per share. This transaction was a mandatory "sell-to-cover" to fulfill tax withholding obligations on restricted stock units (RSUs) that vested on October 1, 2026, and was not a voluntary trade. After the sale, Dube directly held 65,022 shares.

Cathie Wood's ARK Invest Rotates $22 Million in Biotech, Extends Intellia Buying Streak to 50 Sessions

https://finance.biggo.com/news/8052a6fc-21d6-4b0a-99ea-90c0aab80028
Cathie Wood's ARK Invest recently executed a $22 million healthcare portfolio rotation, selling Twist Bioscience while investing in Recursion Pharmaceuticals, Intellia Therapeutics, and Veracyte. This move signifies a strategic shift towards companies with more immediate clinical and diagnostic catalysts within the genomics sector, rather than a retreat from biotech. Notably, ARK has extended its Intellia Therapeutics buying streak to 50 consecutive sessions, anticipating an FDA decision on its CRISPR therapy in March 2027.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement